Guest Speaker:           Charles G. Drake, M.D., Ph.D.

                                    Professor of Oncology

         Professor of Urology

        Co-Director of Prostate Cancer Multi-Disciplinary Clinic

         Johns Hopkins Medicine

                                    Baltimore, M.D.

Topic:                         Cancer Immunotherapy – Progress and Progression

Date:                           Tuesday, December 15, 2015

Time:                          12:00 p.m. – 1:00 p.m.

Location:                    143 Jones Building, Research Drive

Speaker Disclosure:  Charles G. Drake, MD, PhD, has indicated that he has the following relationships with industry to disclose for the participants:  Principal Investigator for Bristol-Myers Squibb, Janssen and Compugen; Inventor for Bristol-Myers Squibb and Potenza Therapeutics; Consultant for Agenus, BMS, Compugen, Dendreon, Medimmune, NexImmune, Novartis, ImmunExcite, Janssen, Lilly, Astra Zeneca, Merck, Pierre Fabre, Potenza Therapeutics, Roche/Genentech, Vesuvius, Sanofi-Aventis and Genentech; Advisory Board Members for Potenza Therapeutics and Tizona Therapeutics.   Stock Ownership (self, less than $10,000) Compugen, Neximmune, Potenza, Tizona.  Patents:  BMS and Janssen.

Activity Medical Director/Planning Committee Disclosure:  Yiping Yang, MD, PhD has indicated he has no relationship with industry to disclose relative to the content of this CME activity.

Accreditation: The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The Duke University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)ä.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Unapproved Use Disclosure: Duke School of Medicine requires CME faculty (speakers) to disclose to the attendees: 1) When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and 2) Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty at this symposium may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.  This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

You must text 919-213-8033 using the code provided at seminar to receive CME credit.

Residents and ACGME Fellows are not eligible for CME.  Pizza and soda will be provided.